 Ahead of Acadia Pharmaceuticals Incs NASDAQ: ACAD FDA AdComm meeting on Friday, the agency officials released their briefing documents, revealing a mixed bag of opinions. The companys resubmitted supplemental New Drug Application for pimavanserin for hallucinations. 